The effect of alendronate on progression of spinal osteophytes and disc-space narrowing

Annals of the Rheumatic Diseases

Volumn 67, Issue 10, 2008, Pages 1427-1430

  Neogi, T ^a,d   Nevitt, M C ^b   Ensrud, K E ^c   Bauer, D ^b   Felson, D T ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d Clinical Epidemiology Research and Training Unit   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; PLACEBO;

AGED; ARTICLE; CHONDROPROTECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOLLOW UP; FRAGILITY FRACTURE; HUMAN; INTERVERTEBRAL DISC SPACE NARROWING; LUMBAR SPINE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; SPINE DISEASE; SPINE RADIOGRAPHY; SPONDYLOSIS; THORACIC SPINE; TREATMENT DURATION; VERTEBRA FRACTURE;

AGED; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; DISEASE PROGRESSION; FEMALE; HUMANS; INTERVERTEBRAL DISK; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOARTHRITIS; OSTEOPHYTE; THORACIC VERTEBRAE;

EID: 53149108976     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.085563     Document Type: Article

References (42)

1. Guccione AA, Felson OT, Anderson JJ, Anthony JM, Zhang Y, Wilson PW, et al. The effects of specific medical conditions on the functional limitations of elders in the Framingham Study. Am J Public Health 1994;84:351-8.
2. Garnero P, Sornay-Rendu E, Arlot M, Christiansen C, Delmas PD. Association between spine disc degeneration and type II collagen degradation in postmenopausal women: the OFELY study. Arthritis Rheum 2004;50:3137-44.
3. Hassett G, Hart DJ, Manek NJ, Doyle DV, Spector TD. Risk factors for progression of lumbar spine disc degeneration: the Chingford Study. Arthritis Rheum 2003;48:3112-7.
4. Resnick D, Niwayama G. Discovertebral destruction in a man with chronic back problems. Invest Radial 1981;16:89-94.
5. Karasik D, Kiel OP. Kiely DK. Cupples LA. Wilson PW. O'Donnell CJ, et al. Abdominal aortic calcification and exostoses at the hand and lumbar spine: the Framingham Study. Calcif Tissue Int 2006;78:1-8.
6. Rogers J, Shepstone L. Dieppe P. Bone formers: osteophyte and enthesophyte formation are positively associated. Ann Rheum Dis 1997;56:85-90.
7. Hayami T, Pickarski M, Wesolowski GA, McLane J, Bone A, Destefano J, et al. The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis Rheum 2004;50:1193-206.
8. Corrado A, Santoro N, Cantatore FP. Extra-skeletal effects of bisphosphonates. Joint Bone Spine 2007;74:32-8.
9. Im Gl, Qureshi SA, Kenney J, Rubash HE, Shanbhag AS. Osteoblast proliferation and maturation by bisphosphonates. Biomaterials 2004;25:4105-15.
10. Meyer JM, Dansereau SM, Farmer RW, Jeans GL, Prenger MC. Bisphosphonates structurally similar to risedronate (actonell slow disease progresion in the guinea pig model of primary arthritis. Arthritis Rheum 2001;44(Suppl 9):S307.
11. Corrado A, Cantatore FP, Grano M, Colucci S. Neridronate and human osteoblasts in normal, osteoporotic and osteoarthritic subjects. Clin Rheumatol 2005;24:527-34.
12. Muehleman C, Green J. Williams JM, Kuettner KE, Thonar EJ, Sumner DR. The effect of bone remodeling inhibition by zoledronic acid in an animal model of cartilage matrix damage. Osteoarthritis Cartilage 2002;10:226-33.
13. Carbone LD, Nevitt MC, Wildy K, Barrow KD, Harris F, Felson D, et al. The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis. Arthritis Rheum 2004;50:3516-25.
14. Fujita T, Fujii Y, Okada SF, Miyauchi A, Takagi Y. Analgesic effect of etidronate on degenerative joint disease. J Bone Miner Metab 2001;19:251-6.
15. Abramson SB. Honig S. Antiresorptive agents and osteoarthritis: more than a bone to pick? Arthritis Rheum 2007;56:2469-73.
16. Black DM. Reiss TF. Nevitt MC, Cauley J, Karpf D. Cummings SR. Design of the Fracture Intervention Trial. Osteoporos Int 1993;3(Suppl 3):S29-39.
17. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group Lancet 1996;348:1535-41.
18. Cummngs SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077-82.
19. Lane NE, Nevitt MC, Genant HK, Hochberg MC. Reliability of new indices of radiographic osteoarthritis of the hand and hip and lumbar disc degeneration. J Rheumatol 1993;20:1911-8.
20. Thompson WD, Walter SD. A reappraisal of the kappa coefficient J Clin Epidemiol 1988;41:949-58.
21. Julkunen H, Heinonen OP, Pyorala K. Hyperostosis of the spine in an adult population. Its relation to hyperglycaemia and obesity. Ann Rheum Dis 1971;30:605-12.
22. Felson DT, Neogi T. Osteoarthritis: is it a disease of cartilage or of bone? Arthritis Rheum 2004;50:341-4.
23. Dieppe P, Cushnaghan J, Young P, Kirwan J. Prediction of the progression of joint space narrowing in osteoarthritis of the knee by bone scintigraphy. Ann Rheum Dis 1993;52:557-63.
24. McCrae F, Shouls J, Dieppe P, Watt I. Scintigraphic assessment of osteoarthritis of the knee joint. Ann Rheum Dis 1992;51:938-42.
25. Zhang Y, Hannan MT, Chaisson CE, McAlindon TE. Evans SR, Aliabadi P. et al. Bone mineral density and risk of incident and progressive radiographic knee osteoarthritis in women: the Framingham Study. J Rheumatol 2000;27:1032-7.
26. Hernandez-Molina G. Neogi T, Hunter DJ, Niu J. Guermazi A, Roemer FW, et al. The association of bone attrition with knee pain and other MRI features of osteoarthritis. Ann Rheum Dis 2008;67:43-7.
27. Nevitt MC, Felson DT. Sex hormones and the risk of osteoarthritis in women: epidemiological evidence. Ann Rheum Dis 1996;55:673-6.
28. Nevitt MC. Cummings SR, Lane NE, Hochberg MC. Scott JC, Pressman AR, et al. Association of oestrogen replacement therapy with the risk of osteoarthritis of the hip in elderly white women. Study of Osteoporotic Fractures Research Group Arch Intern Med 1996;156:2073-80.
29. Nevitt MC, Felson DT, Williams EN, Grady D. The effect of estrogen plus progestin on knee symptoms and related disability in postmenopausal women: The Heart and Estrogen/Progestin Replacement Study, a randomized, double-blind, placebocontrolled trial. Arthritis Rheum 2001;44:811-8.
30. Zhang Y, McAlindon TE. Hannan MT. Chaisson CE, Klein R, Wilson PW. et al. Estrogen replacement therapy and worsening of radiographic knee osteoarthritis: the Framingham Study. Arthritis Rheum 1998;41:1867-73.
31. Manicowt DH, Altman RD, Williams JM, Devogelaer JP, Druetz-Van Egeren A, Lenz ME, et al. Treatment with calcitonin suppresses the responses of bone, cartilage, and synovium in the early stages of canine experimental osteoarthritis and significantly reduces the severity of the cartilage lesions. Arthritis Rheum 1999;42:1159-67.
32. Sondergaard BC. Oestergaard S, Christiansen C, Tankó LB, Karsdal MA. The effect of oral calcitonin on cartilage turnover and surface erosion in an ovariectomized rat model. Arthritis Rheum 2007;56:2674-8.
33. Bruyere O. Delferriere D, Roux C, Wark JD, Spector T, Devogelaer JP, et al. Effects of strontium ranelate on spinal osteoarthritis progression. Ann Rheum Dis 2008;67:335-9.
34. Bingham CO 3rd. Buckland-Wright JC, Gamero P. Cohen SB, Dougados M, Adami S. et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum 2006;54:3494-507.
35. Bucldand-Wrkght JC. Messent EA, Bingham CO 3rd, Ward RJ. Tonkin C. A 2 year longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients. Rheumatology (Oxford) 2007;46:257-64.
36. Spector TD, Conaghan PG, Buckland-Wright JC. Gamero P, Cline GA. Beary JF. et al. Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]. Arthritis Res Ther 2005;7:R625-33.
37. Nevitt MC, Thompson DE. Black DM, Rubin SR, Ensrud K, Yates AJ, et al. Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research Group. Arch Intern Med 2000;160:77-85.
38. Nancoltas GH, Tang R, Phipps RJ, Henneman Z. Guide S. Wu W. et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006;38:617-27.
39. Wada E. Ebara S, Sato S. Ono K. Experimental spondylosis in the rabbit spine. Overuse could accelerate the spondylosis. Spine 1992;17(3 Suppl):S1-6.
40. Pye SR, Reid DM, Lunt M, Adams JE, Silman AJ. O'Neill TW. Lumbar disc degeneration: association between osteophytes, end-plate sclerosis and disc space narrowing. Ann Rheum Dis 2007;66:330-3.
41. Wu DO. Burr DB. Boyd RD. Radin EL Bone and cartilage changes following experimental varus or valgus tibia) angulation. J Orthop Res 1990;8:572-85.
42. Lipson SJ, Muir H. Vertebral osteophyte formation in experimental disc degeneration. Morphologic and proteoglycan changes over time. Arthritis Rheum 1980;23:319-24.